首页> 外文期刊>Current computer-aided drug design >De-novo Drug Design, Molecular Docking and In-Silico Molecular Prediction of AChEI Analogues through CADD Approaches as Anti-Alzheimer's Agents
【24h】

De-novo Drug Design, Molecular Docking and In-Silico Molecular Prediction of AChEI Analogues through CADD Approaches as Anti-Alzheimer's Agents

机译:通过CADD方法作为抗Alzheimer代理商的De-Novo药物设计,分子对接和硅基类类似物的分子预测

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: There are over 44 million persons who suffer with Alzheimer's disease (AD) worldwide, no existence of cure and only symptomatic treatments are available for it. The aim of this study is to evaluate the anti-Alzheimer potential of designed AChEI analogues using computer simulation docking studies. AChEIs are the most potential standards for treatment of AD, because they have proven efficacy. Among all AChEIs donepezil possesses lowest adverse effects, it can treat mild-moderate-severe AD and only once-daily dosing is required. Therefore, donepezil is recognized as a significant prototype for design and development of new drug molecule.
机译:背景:在全世界Alzheimer疾病(广告)中,有超过4400万人患有Alzheimer的疾病,没有治愈的存在,并且只有对症治疗。 本研究的目的是使用计算机仿真对接研究评估设计ACHEI类似物的抗Alzheimer电位。 Acheis是治疗广告的最潜力标准,因为它们已被证明是疗效。 在所有Acheis中,Deppezil都具有最低的不良反应,它可以治疗轻度中度严重的广告,并且只需要一次每日给药。 因此,DodePezil被认为是用于设计和开发新药分子的重要原型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号